NPM1, FLT3, and c-KIT mutations in pediatric acute myeloid leukemia in Russian population

Yuliya Yatsenko1, Olga Kalennik, Mikhail Maschan

  • 1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia. yuliya.yatsenko@gmail.com

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...